Health Canada has authorized Columvi for the treatment of adult patients with r/r DLBCL who have received two or more lines of systemic therapy
The authorization was based on the P-I/II multi-cohort trial (NP30179) evaluating Columvi as monotx. which demonstrated that the therapy induced durable response rates in people with heavily pre-treated large B-cell lymphoma. In the single-arm DLBCL cohort, 84.3% of patients were refractory to their most recent therapy, 34.3% received prior CAR T-cell therapy, 35.2% & 50.0% achieved a CR & objective response
Columvi is a bispecific mAb that binds monovalently to CD3 in the T-cell receptor complex expressed on the surface of T cells & bivalently to CD20 expressed on the surface of B cells
Ref: PRNewswire | Image: Roche
Related News:- Roche’s Hemlibra (emicizumab) Receives the Label Expansion Approval from EC for Moderate Haemophilia A
